BYM338 (Bimagrumab) ( DrugBank: Bimagrumab )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
15	封入体筋炎	2

15. 封入体筋炎

---

臨床試験数 : 42 /  薬物数 : 60 - (DrugBank : 16) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02573467 (ClinicalTrials.gov)	November 2, 2015	9/7/2015	An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203	Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis	Sporadic Inclusion Body Myositis	Drug: Bimagrumab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	36 Years	N/A	All	211	Phase 3	United States;Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom
2	NCT02250443 (ClinicalTrials.gov)	March 11, 2014	20/3/2014	Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis	An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis	Sporadic Inclusion Body Myositis (sIBM)	Drug: BYM338 (Bimagrumab)	Novartis Pharmaceuticals	NULL	Completed	40 Years	75 Years	All	10	Phase 2/Phase 3	United States